Home » Topics » Regulatory » NMPA

NMPA
RSS

UC MSCs show potential in clinical study for SLE

July 30, 2014

China's regulatory authority approves phase II trials of F-351

July 3, 2014

Chinese fast track designation granted to epilepsy drug DP-VPA

June 11, 2014

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical obtains Chinese clinical trial clearance

May 22, 2014

Sihuan Pharmaceutical's application for clinical trial approval for pirotinib accepted in China

Oct. 14, 2013

Lee's Pharmaceutical submits CTA to expand the APEX study to China

Aug. 29, 2013

Lee's Pharmaceutical files to perform pivotal trial of gimatecan for ovarian cancer in China

Aug. 8, 2013

Takeda receives marketing authorization in China for Nesina

Aug. 2, 2013

Beijing Drug Administration accepts Sinovac's filing for EV71 vaccine candidate

May 31, 2013

Sihuan Pharmaceutical cleared to conduct study of DPP IV inhibitor in China

Feb. 26, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...